logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence.

    Article - En anglais

    Background About 50% of alcoholic patients relapse within 3 months of treatment.

    Previous studies have suggested that acamprosate may help to prevent such relapse.

    The aim of our study was to assess the efficacy and safety of long-term acamprosate treatment in alcohol dependence.

    Methods In this multicentre, double-blind, placebo-controlled study, we recruited 455 patients, aged 18-65 years, with chronic or episodic alcohol dependence.

    Patients were randomly allocated treatment with acamprosate (1998 mg daily for bodyweight>60 kg ; 1332 mg daily for ¾60 kg) or placebo for 360 days.

    Patients were assessed on the day treatment started and on days 30,90,180,270, and 360 by interview, self-report, questionnaire, and laboratory screening.

    Patients were classified as abstinent, relapsing, or non-attending.

    Time to first treatment failure (relapse or non-attendance) was the primary outcome measure.

    Findings Seven patients were excluded from the intention-to-treat analysis because they did not attend on the first treatment day and therefore received no medication.

    The acamprosate (n=224) and placebo (n=224) groups were well matched in terms of baseline demographic and alcohol-related variables. 94 acamprosate-treated and 85 placebo-treated patients completed the treatment phase : of those withdrawn, 104 (52 in each group) relapsed, 69 (33 vs 36, respectively) were lost to follow-up, 63 (31 vs 32) refused to continue treatment, 16 (15 vs 11) had concurrent illness,...

    Mots-clés Pascal : Alcoolisme, Dépendance, Acamprosate, Chimiothérapie, Voie orale, Coût, Essai thérapeutique contrôlé, Traitement, Pronostic, Efficacité traitement, Adulte, Homme, Long terme, Vienne, Poitou Charente, France, Europe, Psychopathologie

    Mots-clés Pascal anglais : Alcoholism, Dependence, Chemotherapy, Oral administration, Costs, Controlled therapeutic trial, Treatment, Prognosis, Treatment efficiency, Adult, Human, Long term, Vienne, Poitou-Charente, France, Europe, Psychopathology

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 96-0271141

    Code Inist : 002B02B09D. Création : 199608.